Compare ELVN & FBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELVN | FBNC |
|---|---|---|
| Founded | 2016 | 1934 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2020 | 1995 |
| Metric | ELVN | FBNC |
|---|---|---|
| Price | $40.94 | $61.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $43.40 | ★ $62.25 |
| AVG Volume (30 Days) | ★ 802.4K | 170.8K |
| Earning Date | 05-11-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | 3.17 | ★ 45.65 |
| EPS | N/A | ★ 1.13 |
| Revenue | N/A | ★ $67,623,000.00 |
| Revenue This Year | N/A | $37.82 |
| Revenue Next Year | N/A | $2.30 |
| P/E Ratio | ★ N/A | $53.81 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.79 | $40.01 |
| 52 Week High | $48.53 | $62.64 |
| Indicator | ELVN | FBNC |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | 61.12 |
| Support Level | $38.58 | $56.47 |
| Resistance Level | $41.83 | $62.53 |
| Average True Range (ATR) | 2.20 | 1.39 |
| MACD | 0.04 | 0.24 |
| Stochastic Oscillator | 68.95 | 90.93 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.